Abbott Laboratories reports $44.33 billion revenue for fiscal year ended December 31, 2025, up 5.7%
Abbott Laboratories reported revenue of $44.33 billion for the year ended December 31, 2025, an increase of 5.7% from the previous year ($41.95 billion).
For the same period it posted net income of $6.52 billion, down 51.3%, or $3.72 per diluted share (7.64 a year earlier).
That is a net margin of 14.7%.
On Sanad's AAOIFI Standard 21 screen, Abbott Laboratories is currently compliant: interest-bearing debt is 17.2% of market capitalisation (limit 30%), and impure income is 0.7% of revenue (limit 5%).
Is Abbott Laboratories halal?
See the full AAOIFI screening of Abbott Laboratories
See the full AAOIFI screening of Abbott Laboratories
Source: 10-K filed with the U.S. Securities and Exchange Commission on February 20, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.